Tuo P, Tumolo M, Silvestri G, Vallarino R, Balzarini C, Barretta A, Mazzarello G F, Losurdo G, Mantero E, Fossa S
Unità di terapia intensiva neonatale e pediatrica, Istituto Giannina Gaslini, Genova, Italia.
Pediatr Med Chir. 1992 Mar-Apr;14(2):151-4.
We administered teicoplanin as specific antibiotic therapy for nosocomial "ICU specific" infections with methicillin-resistant Staphylococcus aureus and epidermidis (MRSA-MRSE). The above mentioned drug has been given to 20 patients (15 newborns and 5 not-newborns) admitted into intensive care unit during the years 1988, 1989, 1990 with MRSA-MRSE localized and/or systemic infection, affected by severe disease (RDS, pulmonary edema, congenital cardiac disease, cystic fibrosis) undergoing invasive procedures which presented high nosocomial infective risk (tracheal intubation, mechanical ventilation, venous and arterial cannulation, total parenteral nutrition, etc.). Complete recovery from systemic or localized infection (sepsis, low respiratory tract infection, high respiratory tract infection) occurred in 19 out of 20 patients, with a rate of success of 95%. Teicoplanin treatment lasted from a minimum of nine days to a maximum of thirty days. The dose was 5-6 mg/kg/die in one administration for the first three days, then 4 mg/kg/die. The tolerability of teicoplanin has proven satisfactory, since we had no major side effects during treatment and follow up.
我们使用替考拉宁作为针对耐甲氧西林金黄色葡萄球菌和表皮葡萄球菌（MRSA - MRSE）引起的医院获得性“ICU 特异性”感染的特异性抗生素治疗。在 1988 年、1989 年、1990 年期间，上述药物已给予 20 例患者（15 例新生儿和 5 例非新生儿），这些患者因 MRSA - MRSE 局部和/或全身感染入住重症监护病房，患有严重疾病（呼吸窘迫综合征、肺水肿、先天性心脏病、囊性纤维化）且正在接受具有高医院感染风险的侵入性操作（气管插管、机械通气、动静脉置管、全胃肠外营养等）。20 例患者中有 19 例全身或局部感染（败血症、下呼吸道感染、上呼吸道感染）完全康复，成功率为 95%。替考拉宁治疗持续时间最短为 9 天，最长为 30 天。剂量为前三天每日一次 5 - 6mg/kg，之后为 4mg/kg。替考拉宁的耐受性已被证明令人满意，因为在治疗和随访期间我们未出现重大副作用。
